News
Matchpoint Therapeutics has entered into an exclusive option and license agreement with Novartis to develop and commercialize oral covalent inhibitors.
The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Verastem Oncology’s VS-7375.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback